Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quattroflow™ Introduces 5050 Series Quaternary Diaphragm Pumps

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Ideal for use in demanding biotech and pharmaceutical applications.

Quattroflow™ has announced the introduction of its 5050 Series Quaternary Diaphragm Pump to its family of biotech and pharmaceutical pumps.

This innovative pump system features compact dimensions, multi-directional connections and the ability to satisfy a wide variety of flow-rate requirements, which makes it ideal for use in demanding biotech and pharmaceutical applications.

The 5050 pump provides multi-option installation flexibility and a compact design. The unit is drainable and cleanable, and includes multi-directional pump-head connections and positioning.

The 5050 pump features a 225mm (8.86”) chamber diameter and 50mm (1-1/2”) flange porting.

The 5050 pump has a wide flow range from 50 to 5,000 L/hr (13 to 1,321 gph), with maximum pressure to 6 bar at 20°C (87 psi at 68°F). The complete flow range can be achieved with one drive, no further drive options needed.

The pump chamber is available in 316L stainless steel for multiple-use and polypropylene (PP) for single-use applications. The pump’s valves are constructed of EPDM, while the diaphragm is Santoprene® (EPDM/PP compound).

Quattroflow’s positive displacement pumps incorporate a four piston-diaphragm technology with no mechanical seals that is driven by an eccentric shaft and motor.

Quattroflow products primarily serve the biotech and pharmaceutical industries that require gentle displacement, reliability, product safety, purity and cleanability.

The 5050 pump can be found in multiple or single-use applications within cross-flow systems, chromatography devices and centrifuges.

Quattroflow is a leading brand from Almatec, which is part of Dover Corporation’s Pump Solutions Group (PSG®).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!